IRCT138810203032N1已完成未知
Comparsion of combination therapy with Deferiprone plus desferrioxamine versus desferrioxamine alone in patients with major beta thalassemia
Mazndaran University of Medical Science0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 5 years 至 30 years（—）
- 性别
- All
入选标准
- •1- Confirmed major thalassemia by Hemoglubin elctrophoresis
- •2- Age ranged 5-30 years
- •3- Serum ferritin level more than 3000 ng/ml
- •4- Written consent from patients or parents
- •Exclusion criteria:
- •1- Disagreement of patients or parents for begining of treatment
- •2- Deferiprone sensitivity
- •3- Desferrioxamine sensitivity
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Treatment of iron overload in thalassemia patientsThalassemia.Beta thalassaemiaIRCT2016041627412N1Vice Chancellor for research of Urmia University of Medical Sciences36
已完成
2 期
Deferiprone for the Treatment of Parkinson’s DiseaseEarly-stage Parkinson’s diseaseNeurological - Parkinson's diseaseACTRN12617001578392ApoPharma Inc.36
已完成
2 期
Desmopressin plus tolterodine versus desmopressin plus indomethacin for pediatric enuresisPediatric enuresis.Nocturnal enuresisN39.44IRCT20210613051564N140
已完成
不适用
Combination therapy in rheumatoid arthritisRheumatoid arthritisISRCTN18445519Turku University Hospital (Finland)199
进行中（未招募）
1 期
An international open label trial of deferiprone in patients with iron storage brain disorders - an extension to TIRCON2012V1 (a randomised controlled trial of deferiprone in patients with iron storage brain disorders).EUCTR2014-001427-79-GBApoPharma Inc89